CN106174466A - 一种口服营养组合物 - Google Patents
一种口服营养组合物 Download PDFInfo
- Publication number
- CN106174466A CN106174466A CN201610363931.7A CN201610363931A CN106174466A CN 106174466 A CN106174466 A CN 106174466A CN 201610363931 A CN201610363931 A CN 201610363931A CN 106174466 A CN106174466 A CN 106174466A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- nutrition composition
- phylloxanthin
- egcg
- oral nutrition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 235000021542 oral nutrition Nutrition 0.000 title claims abstract description 29
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 50
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 36
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 19
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940046009 vitamin E Drugs 0.000 claims abstract description 19
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 19
- 239000011709 vitamin E Substances 0.000 claims abstract description 19
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 17
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 17
- 239000011718 vitamin C Substances 0.000 claims abstract description 17
- 230000003064 anti-oxidating effect Effects 0.000 claims abstract description 15
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 12
- 229960000984 tocofersolan Drugs 0.000 claims description 11
- 239000002076 α-tocopherol Substances 0.000 claims description 10
- 235000004835 α-tocopherol Nutrition 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 abstract description 4
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 abstract description 4
- 229940030275 epigallocatechin gallate Drugs 0.000 abstract description 4
- 150000003254 radicals Chemical class 0.000 description 10
- 230000003647 oxidation Effects 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- -1 nitric oxide free radical Chemical class 0.000 description 5
- 230000032683 aging Effects 0.000 description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 2
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- IELOKBJPULMYRW-IKTKBOKFSA-N 4-oxo-4-[[(2S)-2,5,7,8-tetramethyl-2-[(4S,8S)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl]oxy]butanoic acid Chemical compound CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(CC1)Oc(c(C)c2C)c1c(C)c2OC(CCC(O)=O)=O IELOKBJPULMYRW-IKTKBOKFSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- 239000011740 D-alpha-tocopherylacetate Substances 0.000 description 1
- 235000002414 D-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000000785 Tagetes erecta Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FMMSEFNIWDFLKK-UHFFFAOYSA-N [O].OO Chemical compound [O].OO FMMSEFNIWDFLKK-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 229940039770 d-alpha-tocopheryl acetate Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种口服营养组合物,更具体地,本发明提供了一种具有抗氧化功能的口服营养组合物,其包含以一定比例组合的维生素C、维生素E、叶黄素和表没食子儿茶素没食子酸酯(EGCG)。
Description
技术领域
本发明涉及一种组合物。具体地,本发明涉及一种具有抗氧化功能的口服营养组合物。
背景技术
自由基,化学上也称为“游离基”,是含有一个不成对电子的原子团。由于原子形成分子时,化学键中电子必须成对出现,因此自由基会夺取其它物质的一个电子,使自己形成稳定的物质。在化学中,这种现象称为“氧化”。生物体系内主要是氧自由基,例如超氧阴离子自由基、羟自由基、脂氧自由基、二氧化氮和一氧化氮自由基,及称为活性氧的过氧化氢、单线态氧和臭氧。体内活性氧自由基具有一定的功能,如参与免疫和信号传导过程,但过多的活性氧自由基就会有破坏作用。自由基学说认为体内过多的氧自由基诱发脂质过氧化,引起细胞的破坏、衰亡,最终导致机体的衰老和功能障碍。
要降低自由基对人体的危害,除了依靠体内自由基清除系统外,还要寻找和发掘外源性自由基清除剂。研究表明,体内自由基清除系统的功能有赖于合理的膳食营养和充足的抗氧化营养素的摄入,构成体内抗氧化酶类系统如SOD、GSH-Px所必需的硒、锌、铜、锰,以及抗氧化营养素如VC、VE、β-胡萝卜素等,都无法在体内自行合成,必须从食物中摄取,因此膳食营养对保持人体内的正常的抗氧化功能起着重要的作用。摄入膳食剂量的抗氧化营养成分不仅安全,而且还可以减轻体内的脂质过氧化,提高体内抗氧化酶的活性,对增强机体抗氧化能力,延缓衰老有重要作用。
维生素C、维生素E和叶黄素是本领域常用的抗氧化剂,可抑制活性氧自由基的活性。表没食子儿茶素没食子酸酯(EGCG)是存在于茶叶中的多酚类化合物,具有很强的清除自由基的作用。本发明人惊奇地发现,将维生素C、维生素E、叶黄素和EGCG以一定比例组合可以提供增强的抗氧化作用,从而提供一种具有增强抗氧化作用的口服营养组合物。
发明内容
本发明提供了一种口服营养组合物,其包含维生素C、维生素E、叶黄素和表没食子儿茶素没食子酸酯(EGCG)。该口服营养组合物在抗氧化方面具有协同作用,因而可用于增强人体的抗氧化能力,从而延缓衰老。
所述维生素C可以是L-抗坏血酸、L-抗坏血酸钙、维生素C磷酸酯镁、L-抗坏血酸钠、L-抗坏血酸钾、L-抗坏血酸-6-棕榈酸盐和/或抗坏血酸棕榈酸酯等。
所述维生素E可以是d-α-生育酚、dl-α-生育酚、d-α-醋酸生育酚、dl-α-醋酸生育酚、混合生育酚浓缩液、d-α-琥珀酸生育酚和/或dl-α-琥珀酸生育酚,和/或其酯等。
所述维生素C、维生素E、叶黄素和EGCG可以是合成的或天然来源的。例如,所述维生素C可以是富含维生素C的植物提取物如刺梨提取物,所述叶黄素可以是万寿菊花的提取物,所述EGCG可以是茶叶提取物或茶多酚提取物,如(DSM,荷兰)。
在本发明的所述口服营养组合物中,所述维生素C的重量(以L-抗坏血酸计算)可以是叶黄素重量的2-30倍,优选5-20倍,更优选8-15倍,如8、9、10、11、12、13、14或15倍;所述维生素E的重量(以d-α-生育酚计算)可以是叶黄素重量的0.2-10倍,优选0.5-8倍,更优选0.8-3倍,如0.8、1、1.5、2、2.5或3倍;所述EGCG的重量可以是叶黄素重量的2-30倍,优选3-20倍,更优选4-10倍,如4、5、6、7、8、9或10倍。
优选地,在本发明的所述口服营养组合物中,所述维生素C的重量百分含量(以L-抗坏血酸计算)可以为2%-30%,优选5%-20%,更优选8%-15%,最优选10%;所述维生素E的重量百分含量(以d-α-生育酚计算)可以为0.2%-10%,优选0.5-5%,更优选0.8-2%,最优选1%;所述叶黄素的重量百分含量可以为0.2%-10%,优选0.5-5%,更优选0.8-2%,最优选1%;所述EGCG的重量百分含量可以为2%-30%,优选3%-20%,更优选4%-10%,最优选5%。
优选地,本发明的所述口服营养组合物含有20-300mg,更优选30-200mg,最优选50-100mg的维生素C(以L-抗坏血酸计算);2-100mg,更优选3-50mg,最优选5-10mg的维生素E(以d-α-生育酚计算);2-100mg,更优选3-50mg,最优选5-10mg的叶黄素;和10-150mg,更优选20-100mg,最优选25-50mg的EGCG。在一个实施方案中,所述组合物包含100mg维生素C(以L-抗坏血酸计算)、10mg维生素E(以d-α-生育酚计算)、10mg叶黄素、和50mg EGCG。在另一个实施方案中,所述组合物包含50mg维生素C(以L-抗坏血酸计算)、5mg维生素E(以d-α-生育酚计算)、5mg叶黄素、和25mg EGCG。
任选地,本发明的所述口服营养组合物还可以含有辅料。该辅料的例子包括但不限于保护性水胶体(如胶质、蛋白质和改性的淀粉)、粘合剂(如硬脂酸镁等)、成膜剂、包封剂、壁/壳材料、基质化合物、包衣、乳化剂、表面活性剂、增溶剂(油、脂肪、蜡和卵磷脂等)、吸附剂、载体、填充剂、分散剂(如乳糖等)、湿润剂、操作助剂(如溶剂)、流动剂(如微晶纤维素、二氧化硅等)、遮味剂、增重剂、胶冻剂、凝胶形成剂、抗氧化剂和抗微生物剂等。该辅料的更具体的例子或其它辅料是本领域公知的,可参见“Remington:The Science andPractice of Pharmacy”,Williams and Wilking(Publisher)2000,在此将其引为参考。
本发明的所述口服营养组合物可以是任何适于人口服使用的形式,例如但不限于粉剂、片剂、丸剂、颗粒剂、锭剂、胶囊(软或硬胶囊)、口服液、冲剂和泡腾配方。该口服营养组合物可以是受控(延迟)释放的形式。
本发明的所述口服营养组合物在抗氧化方面具有协同作用,因而可用于增强人体的抗氧化能力,从而延缓衰老。因此,本发明还提供了本发明的所述口服营养组合物在用于制备人体抗氧化和/或延缓人体衰老的制剂中用途。
在将本发明的所述口服营养组合物用于人体抗氧化和/或延缓人体衰老中时,本发明的所述口服用组合物可以以任何合适的量向人施用。优选地,本发明的所述组合物以20-600mg/d维生素C(以L-抗坏血酸计算)、2-200mg/d维生素E(以d-α-生育酚计算)、2-200mg/d叶黄素和10-300mg/d EGCG的量分一次或多次向人施用。更优选地,本发明的所述口服营养组合物以50-100mg/d维生素C(以L-抗坏血酸计算)、5-10mg/d维生素E(以d-α-生育酚计算)、5-10mg/d叶黄素和25-50mg/d EGCG的量分一次或多次向人施用。
在本发明中,“协同作用”是指两种或多种物质相互联系、相互配合、相互协调,其效果比每种物质单独起作用的效果之和大,即1+1>2的现象,或者是指一种物质因另一种物质的存在而效果得到增强的现象,后一种现象也可以称作“相互促进作用”。本发明的所述口服营养组合物在抗氧化方面的相互促进或协同作用可以通过本领域公知的设备如或方法例如细胞学实验、动物实验或人体试验等来检测。
下文提供了的实施例,用以对本发明作进一步的说明。这些实施例仅是为了说明的目的,不能解释为以任何方式限制本发明的范围。
实施例
实施例1.口服营养组合物
将下列组分按所示剂量混合,制得本发明的所述口服营养组合物。
实施例2.本发明所述组合物的抗氧化能力测试
将维生素C、维生素E、叶黄素和EGCG分别或其组合加入到精制猪油中制备成预定浓度的溶液,取5g该溶液加入到油脂氧化稳定性测定仪Rancimat 743(劢强科技(中国)有限公司,上海)中按照说明书的操作来测量这些组分及其组合的抗氧化作用,以不加任何组分的5g精制猪油作为对照。测量温度为120℃,进气速度为20l/h,温度修正设定为(Delta):2℃。测量结果如下:
测量结果表明,所述组分及其组合能够延缓精制猪油的氧化,但是所述组合延缓精制猪油氧化的时间比任一单一组分延缓氧化的时间都要长,且比各单一组分延缓氧化的时间的和都要长,可见,所述组合在抗氧化方面具有协同作用。
实施例3.本发明所述组合物的人体试食试验
向受试者口服给予本发明的所述组合物样品,该样品含有31.33mg EGCG、6g叶黄素、9g dl-α-生育酚醋酸酯和60g L-抗坏血酸。
试验按双盲法进行,采用自身和组间两种对照设计。对受试者按MDA(过氧化脂质)、SOD(超氧化物歧化酶)、GSH-Px(谷胱甘肽过氧化物酶)水平随机分为试食组和对照组,尽可能考虑影响结果的主要因素如年龄、性别、生活饮食习惯等,进行均衡性检验,以保证组间的可比性。试食组每天两次服用所述样品,对照组服用安慰剂,连续180天。试验期间对照组和试食组原生活、饮食不变。
受试者年龄18-65岁,身体健康状况良好,无明显脑、心肝、肺、肾、血液病患,无长期服药史。初始试验人群试食组53例,对照组53例,试食前后,受试者精神、睡眠、饮食、大小便状况未见异常。对照组:男/女为16/37,年龄为47.89±9.90岁;试食组:男/女为16/37,年龄为48.00±9.58岁。
受试者服用本发明的所述样品180天后,结果表明:试食后试食组血清SOD、GSH-Px活力分别较试验前提高10.80%、11.94%,血清MDA较试验前降低6.06%,其中SOD和GSH-Px活力与对照组试食后及自身试验前比较,差异均有显著性(P<0.05)。试食前后体重,血压、心率均未见明显异常改变,血常规、尿常规、大便常规、生化检测、心电图、B超、胸透等安全性指标均在正常范围内。试食期间未见与样品有关的不良反应。上述结果表明所述样品具有抗氧化功能。
Claims (10)
1.一种口服营养组合物,其包含维生素C、维生素E、叶黄素和表没食子儿茶素没食子酸酯(EGCG)。
2.如权利要求1所述的口服营养组合物,其中维生素C、维生素E、叶黄素和EGCG可以是合成的或天然来源的。
3.如权利要求1所述的口服营养组合物,其中所述维生素C的重量(以L-抗坏血酸计算)可以是叶黄素重量的2-30倍,优选5-20倍,更优选8-15倍,如8、9、10、11、12、13、14或15倍;所述维生素E的重量(以d-α-生育酚计算)可以是叶黄素重量的0.2-10倍,优选0.5-8倍,更优选0.8-3倍,如0.8、1、1.5、2、2.5或3倍;所述EGCG的重量可以是叶黄素重量的2-30倍,优选3-20倍,更优选4-10倍,如4、5、6、7、8、9或10倍。
4.如权利要求1所述的口服营养组合物,其中所述维生素C的重量百分含量(以L-抗坏血酸计算)可以为2%-30%,优选5%-20%,更优选8%-15%,最优选10%;所述维生素E的重量百分含量(以L-抗坏血酸计算)可以为0.2%-10%,优选0.5-5%,更优选0.8-2%,最优选1%;所述叶黄素的重量百分含量可以为0.2%-10%,优选0.5-5%,更优选0.8-2%,最优选1%;所述EGCG的重量百分含量可以为2%-30%,优选3%-20%,更优选4%-10%,最优选5%。
5.如权利要求1所述的口服营养组合物,其含有20-300mg,更优选30-200mg,最优选50-100mg的维生素C(以L-抗坏血酸计算);2-100mg,更优选3-50mg,最优选5-10mg的维生素E(以d-α-生育酚计算);2-100mg,更优选3-50mg,最优选5-10mg的叶黄素;和10-150mg,更优选20-100mg,最优选25-50mg的EGCG。
6.如权利要求1所述的口服营养组合物,其含有100mg维生素C(以L-抗坏血酸计算)、10mg维生素E(以d-α-生育酚计算)、10mg叶黄素、和50mg EGCG。
7.如权利要求1所述的口服营养组合物,其含有50mg维生素C(以L-抗坏血酸计算)、5mg维生素E(以d-α-生育酚计算)、5mg叶黄素、和25mg EGCG。
8.如权利要求1所述的口服营养组合物,其还含有辅料。
9.如权利要求1所述的口服营养组合物,其为粉剂、片剂、丸剂、颗粒剂、锭剂、胶囊(软或硬胶囊)、口服液、冲剂和泡腾配方的形式,或受控(延迟)释放的形式。
10.如权利要求1所述的口服营养组合物在用于制备人体抗氧化和/或延缓人体衰老的制剂中用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015102763365 | 2015-05-26 | ||
CN201510276336 | 2015-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106174466A true CN106174466A (zh) | 2016-12-07 |
Family
ID=57453065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610363931.7A Pending CN106174466A (zh) | 2015-05-26 | 2016-05-26 | 一种口服营养组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106174466A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112867486A (zh) * | 2018-10-22 | 2021-05-28 | 帝斯曼知识产权资产管理有限公司 | 表现出增强的氧化稳定性的组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1535116A (zh) * | 2001-03-23 | 2004-10-06 | ʿ | 用于治疗黄斑变性的营养补剂 |
CN101026966A (zh) * | 2004-09-27 | 2007-08-29 | 雀巢技术公司 | 护肤饮料组合物 |
WO2007113007A2 (en) * | 2006-04-04 | 2007-10-11 | Dsm Ip Assets B.V. | Package containing a polyphenol and their uses |
CN103610144A (zh) * | 2013-11-30 | 2014-03-05 | 大连润扬科技发展有限公司 | 一种降糖核桃粉及其制备方法 |
-
2016
- 2016-05-26 CN CN201610363931.7A patent/CN106174466A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1535116A (zh) * | 2001-03-23 | 2004-10-06 | ʿ | 用于治疗黄斑变性的营养补剂 |
CN101026966A (zh) * | 2004-09-27 | 2007-08-29 | 雀巢技术公司 | 护肤饮料组合物 |
WO2007113007A2 (en) * | 2006-04-04 | 2007-10-11 | Dsm Ip Assets B.V. | Package containing a polyphenol and their uses |
CN103610144A (zh) * | 2013-11-30 | 2014-03-05 | 大连润扬科技发展有限公司 | 一种降糖核桃粉及其制备方法 |
Non-Patent Citations (2)
Title |
---|
中国食品添加剂和配料协会编著: "《"十一五"国家重点图书出版规划项目 食品添加剂手册 第3版》", 30 September 2012, 中国轻工业出版社 * |
李殿鑫: "《饮食营养与健康》", 30 September 2011, 华中科技大学出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112867486A (zh) * | 2018-10-22 | 2021-05-28 | 帝斯曼知识产权资产管理有限公司 | 表现出增强的氧化稳定性的组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101661246B1 (ko) | 흡수 및 생물학적 이용 증진을 위한 완전 천연 종합 비타민 및 종합 미네랄 건강 보조제 | |
WO2001049285A1 (en) | Flavonoid drug and dosage form, its production and use | |
WO2006023814A2 (en) | Effervescent composition including a grape-derived component | |
WO2009055084A2 (en) | Vitamin c compositions | |
JP2013151451A (ja) | ツリフネソウ抽出物を含む抗酸化・抗アレルギー剤 | |
WO2009062662A1 (en) | Pharmaceutical and nutraceutical compositions based on menaquinols | |
US20110280855A1 (en) | Vitamin c compositions | |
US20190223486A1 (en) | Catechin absorption enhancer for enhancing catechin absorption in small intestinal epithelial cells | |
KR102100295B1 (ko) | 간세포 보호 효과 및 골 밀도 증가 효과를 갖는 쿠메스테롤 함유 발아발효콩 추출물 및 이를 포함하는 조성물 | |
CN106174466A (zh) | 一种口服营养组合物 | |
EP3448370B1 (en) | Composition for the treatment of polycystic ovary syndrome | |
JP6045164B2 (ja) | 長命草ポリフェノール並びにビタミンe及び/又はビタミンcを含む組成物 | |
KR20120073720A (ko) | 디프테로카퍼스 옵터시포리어스 추출물을 유효성분으로 함유하는 노화방지용 조성물 | |
CN106890140B (zh) | d-柠檬烯抗癌增效组合物及其制备方法与应用 | |
WO2016135482A1 (en) | Compositions comprising co-q10, krill oil and vitamin d | |
JP2004315476A (ja) | ヒアルロニダーゼ阻害剤 | |
Safitri et al. | The effects of Caesalpinia sappan L. Extract granule to antioxidant activity in blood serum of wistar rat (rattus norvegicus) with excessive iron condition | |
KR20150104950A (ko) | 헤스페레틴 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 방사선에 의한 세포 또는 조직 손상 예방 및 치료용 약학적 조성물 | |
KR101672827B1 (ko) | 알라스칸 진생의 잎 추출물을 유효성분으로 함유하는 항산화 또는 항염증용 약학 조성물 | |
JP7407515B2 (ja) | 内服用組成物 | |
CN108430486B (zh) | 含有香豆雌酚的发芽发酵豆提取物及包含其的组合物 | |
CN118160923A (zh) | 一种抗氧化组合物及其应用 | |
WO2024124239A2 (en) | Dietary supplement and methods of use thereof | |
KR20130009649A (ko) | 로도덴드론 알붐 추출물 또는 이의 분획물을 유효성분으로 함유하는 항산화용 조성물 | |
KR101416572B1 (ko) | 마스티시아 알보리아 추출물 또는 이의 분획물을 유효성분으로 함유하는 노화방지용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |